The NALA trial has shown that combining neratinib with capecitabine leads to a significant improvement in PFS when compared to lapatinib plus capecitabine, presenting a viable treatment option for previously treated patients with HER2-positive metastatic BC. The gene discussed is ERBB2; the disease is breast cancer.